Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shaoqi Yikun is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Third Affiliated Hospital of Nanjing University of Chinese Medicine (Nanjing Hospital of Chinese Medicine) for the treatment of menopausal syndrome (perimenopausal syndrome). The formula is designed to nourish the liver and kidney yin and regulate the Chong and Ren meridians, addressing the core TCM etiology of menopausal symptoms. It typically contains herbal ingredients such as Radix Paeoniae Alba (Bai Shao) and Fructus Lycii (Gou Qi Zi). Clinical research indicates that Shaoqi Yikun effectively modulates the hypothalamus-pituitary-ovarian (HPO) axis, leading to increased serum estradiol (E2) levels and decreased levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This hormonal stabilization helps alleviate clinical symptoms such as hot flashes, night sweats, irritability, and sleep disturbances in perimenopausal women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shaoqi Yikun.